Following exclusion of all patients identified as having presumed HER2-positive disease, reanalysis demonstrated a large benefit of chemotherapy remained for patients whose breast cancers were positive for ER, presumably negative for HER2, and who had an RS ≥ 31. Here, ERBB2 is linked to breast carcinoma.